Radnor Capital Management LLC Sells 326 Shares of Becton, Dickinson and Company (NYSE:BDX)

Radnor Capital Management LLC cut its holdings in Becton, Dickinson and Company (NYSE:BDX) by 11.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,611 shares of the medical instruments supplier’s stock after selling 326 shares during the period. Radnor Capital Management LLC’s holdings in Becton, Dickinson and Company were worth $592,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Livelsberger Financial Advisory bought a new position in Becton, Dickinson and Company in the 3rd quarter worth $26,000. Ashton Thomas Securities LLC bought a new position in shares of Becton, Dickinson and Company in the third quarter worth about $33,000. Tompkins Financial Corp raised its stake in shares of Becton, Dickinson and Company by 44.2% in the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 46 shares during the period. Sound Income Strategies LLC grew its stake in shares of Becton, Dickinson and Company by 35.8% during the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 44 shares during the period. Finally, Kennebec Savings Bank bought a new position in shares of Becton, Dickinson and Company during the 3rd quarter valued at approximately $46,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX opened at $232.70 on Thursday. The firm has a market cap of $67.48 billion, a price-to-earnings ratio of 39.18, a P/E/G ratio of 1.64 and a beta of 0.39. The firm has a fifty day moving average price of $226.92 and a 200 day moving average price of $232.50. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $248.42. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.17.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, beating the consensus estimate of $3.77 by $0.04. The business had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The business’s revenue was up 6.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.42 EPS. As a group, sell-side analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th were issued a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 1.79%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. The ex-dividend date was Monday, December 9th. Becton, Dickinson and Company’s dividend payout ratio is 70.03%.

Wall Street Analysts Forecast Growth

BDX has been the topic of several analyst reports. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price target for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. StockNews.com cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Finally, Evercore ISI increased their price target on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $283.50.

Insider Activity

In related news, EVP Shana Carol Neal sold 788 shares of the stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total value of $185,180.00. Following the completion of the transaction, the executive vice president now owns 16,201 shares of the company’s stock, valued at approximately $3,807,235. This trade represents a 4.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael David Garrison sold 2,838 shares of the business’s stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $223.33, for a total value of $633,810.54. Following the sale, the executive vice president now directly owns 6,141 shares in the company, valued at $1,371,469.53. The trade was a 31.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 8,747 shares of company stock worth $1,949,520. 0.36% of the stock is currently owned by insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.